S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Sanofi Stock Forecast, Price & News

+0.05 (+0.10 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $49.69
50-Day Range
MA: $48.31
52-Week Range
Now: $49.69
Volume3.10 million shs
Average Volume3.17 million shs
Market Capitalization$124.43 billion
P/E Ratio21.24
Dividend Yield2.36%
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.


Overall MarketRank

1.94 out of 5 stars

Medical Sector

73rd out of 1,925 stocks

Pharmaceutical Preparations Industry

32nd out of 773 stocks

Analyst Opinion: 2.2Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SNY
Phone33 1 53 77 40 00



Sales & Book Value

Annual Sales$40.00 billion
Cash Flow$6.87 per share
Book Value$26.44 per share


Net Income$3.26 billion


Outstanding Shares2,504,140,000
Market Cap$124.43 billion
Next Earnings Date2/5/2021 (Confirmed)
+0.05 (+0.10 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sanofi (NASDAQ:SNY) Frequently Asked Questions

How has Sanofi's stock been impacted by COVID-19 (Coronavirus)?

Sanofi's stock was trading at $44.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNY shares have increased by 10.9% and is now trading at $49.69.
View which stocks have been most impacted by COVID-19

Is Sanofi a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sanofi stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.
View analyst ratings for Sanofi
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Sanofi?

Wall Street analysts have given Sanofi a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sanofi wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Sanofi's CEO?

1,448 employees have rated Sanofi CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Sanofi's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Sanofi's next earnings date?

Sanofi is scheduled to release its next quarterly earnings announcement on Friday, February 5th 2021.
View our earnings forecast for Sanofi

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) issued its quarterly earnings results on Thursday, October, 29th. The company reported $1.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.08 by $0.01. The company earned $11.08 billion during the quarter, compared to the consensus estimate of $11.82 billion. Sanofi had a return on equity of 24.77% and a net margin of 14.49%.
View Sanofi's earnings history

Is Sanofi a good dividend stock?

Sanofi pays an annual dividend of $1.17 per share and currently has a dividend yield of 2.36%. The dividend payout ratio of Sanofi is 35.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Sanofi will have a dividend payout ratio of 31.28% next year. This indicates that Sanofi will be able to sustain or increase its dividend.
View Sanofi's dividend history.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi updated its FY 2020 Pre-Market earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of 7.00-7.14 for the period.

What price target have analysts set for SNY?

11 brokerages have issued twelve-month price targets for Sanofi's stock. Their forecasts range from $56.00 to $58.00. On average, they anticipate Sanofi's share price to reach $57.00 in the next year. This suggests a possible upside of 14.7% from the stock's current price.
View analysts' price targets for Sanofi
or view Wall Street analyst' top-rated stocks.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), (AZN), The Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Paul Hudson, CEO & Director (Age 54)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 56)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik C.F.A., CPA, CFA, Head of Investor Relations
  • Ms. Karen Linehan, Exec. VP of Legal Affairs & Gen. Counsel (Age 62)
  • Mr. Dante Beccaria, Global Compliance Officer & VP
  • Mr. Josep Catlla, Head of Communications
  • Mr. Pierre Chancel, Sr. VP of Global Diabetes and Sr. VP of Global Marketing (Age 64)
  • Ms. Natalie Bickford, Exec. VP & Chief People Officer

What is Sanofi's stock symbol?

Sanofi trades on the NASDAQ under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of institutional and retail investors. Top institutional investors include Kestra Advisory Services LLC (0.01%), ProVise Management Group LLC (0.01%), Pacer Advisors Inc. (0.00%), Candriam Luxembourg S.C.A. (0.00%), Holloway Wealth Management LLC (0.00%) and Crossmark Global Holdings Inc. (0.00%).
View institutional ownership trends for Sanofi

Which major investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, DT Investment Partners LLC, Ritholtz Wealth Management, Raymond James Trust N.A., Avantax Advisory Services Inc., Thomasville National Bank, JustInvest LLC, and Hohimer Wealth Management LLC.
View insider buying and selling activity for Sanofi
or view top insider-selling stocks.

Which major investors are buying Sanofi stock?

SNY stock was acquired by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Pacer Advisors Inc., Candriam Luxembourg S.C.A., Altfest L J & Co. Inc., Crescent Capital Consulting LLC, Park Avenue Securities LLC, Kestra Private Wealth Services LLC, and Holloway Wealth Management LLC.
View insider buying and selling activity for Sanofi
or or view top insider-buying stocks.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $49.69.

How big of a company is Sanofi?

Sanofi has a market capitalization of $124.43 billion and generates $40.00 billion in revenue each year. The company earns $3.26 billion in net income (profit) each year or $3.32 on an earnings per share basis. Sanofi employs 100,409 workers across the globe.

What is Sanofi's official website?

The official website for Sanofi is www.sanofi.com.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33 1 53 77 40 00 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.